About Acorda Therapeutics Inc - Company Information, Overview, History and Profile
What does Acorda Therapeutics Inc do?
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis. The company's Net product revenue is derived from the sales of Ampyra and Inbrija.
Acorda Therapeutics Inc Management structure
All Gross Remunerations are in USD
Dr. Ron Cohen, M.D.
Director, President and Chief Executive Officer
984.15 K
2022
Gross Remuneration
Year
Mr. Kerry Clem
Chief Commercial Officer
592.23 K
2022
Gross Remuneration
Year
Ms. Lauren M. Sabella
Executive Vice President and Chief Operating Officer
530.27 K
2022
Gross Remuneration
Year
Mr. Michael A. Gesser
Treasurer, Chief Financial Officer and Principal Accounting Officer
459.15 K
2022
Gross Remuneration
Year
Mr. Neil S. Belloff
General Counsel and Corporate Secretary
-
2022
Gross Remuneration
Year
Ms. Sofia Ali
Senior Vice President, Operations and Strategic Planning